Scarring
Peptides explored for scarring — GHK-Cu, AC-SDKP, copper peptides — with mechanism rationale for matrix remodeling and anti-fibrotic effects, evidence in different scar types, and how peptide therapy fits alongside conventional scar management.
Scarring is the natural endpoint of dermal injury — wound healing produces collagen-rich tissue that may be cosmetically and functionally distinct from normal skin. Scar morphology varies widely: normotrophic scars (the goal of optimal healing); hypertrophic scars (raised, within original wound boundary); keloids (raised, extending beyond wound boundary, with strong genetic predisposition); atrophic scars (depressed, common after acne, including ice-pick, boxcar, and rolling subtypes); contracture scars (after burns, restricting movement); and pigmented scars. Each scar type responds differently to treatment.
Conventional management depends on scar type. Hypertrophic scars and keloids: intralesional corticosteroid injection (triamcinolone), silicone gel sheets, pressure therapy, cryotherapy, surgical excision (with high recurrence risk for keloids), laser therapy. Atrophic scars (most commonly post-acne): microneedling, fractional laser resurfacing, subcision, dermal fillers, chemical peels. Surgical scars: silicone gel, sun protection, time. Pigmented scars: hydroquinone, retinoids, sun protection.
Peptide therapy has come up across scar types, with different peptides relevant to different scar mechanisms. GHK-Cu has matrix remodeling and anti-inflammatory effects relevant to most scar types. AC-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline) has anti-fibrotic activity particularly relevant to hypertrophic scarring and keloids. Copper peptides broadly support skin healing. Matrixyl and related collagen-stimulating peptides may help atrophic scars.
The honest framing: peptides may add modest improvement to comprehensive scar management, particularly when combined with procedural therapy. They do not replace established interventions for established scars (intralesional steroids for hypertrophic/keloids, procedural therapy for atrophic scars).
This page covers what's actually known about peptides for scarring, where the evidence is strongest, how peptide therapy fits alongside conventional scar management, and important caveats. It is informational, not medical advice.
Peptides discussed for Scarring
GHK-Cu
Copper Peptide
The most-studied copper peptide in skincare — a naturally occurring tripeptide (GHK, Gly-His-Lys) whose active tissue form is the copper complex GHK-Cu, with extensive evidence for skin remodeling, collagen synthesis, wound healing, and anti-aging.
BPC-157
Gastric Peptide
A synthetic peptide derived from a protective protein found in gastric juice, widely discussed for tissue repair and recovery.
Matrixyl
Signal Peptide (Cosmetic)
A collagen-stimulating cosmetic peptide that signals skin to produce more collagen and extracellular matrix proteins.
TB-500
Tissue Repair Peptide
A synthetic version of the active region of thymosin beta-4, widely used for tissue repair, wound healing, and recovery from injuries.
Ac-SDKP
Endogenous Antifibrotic Peptide
An endogenous tetrapeptide cleaved from thymosin β4 with broad antifibrotic activity across the heart, kidney, lung, and liver — historically developed as the chemoprotective drug goralatide and more recently studied as a biomarker of ACE-inhibitor activity.
AHK-Cu
Copper Peptide
A copper peptide — the copper-complexed tripeptide alanine-histidine-lysine (AHK-Cu, Copper Tripeptide-3) — studied for hair follicle stimulation and dermal papilla cell survival. A structural cousin of the better-known copper peptide GHK-Cu with a distinct, hair-focused research profile.
How peptides target scarring
GHK-Cu has the broadest application across scar types. Its mechanisms — modulation of matrix metalloproteinases, regulation of collagen synthesis (favoring type I/III balance), anti-inflammatory effects, and copper-driven lysyl oxidase activity for normal collagen crosslinking — align with the goals of normalizing scar architecture rather than producing disorganized fibrotic tissue. GHK-Cu is widely used in post-procedure recovery and post-surgical scar protocols.
AC-SDKP is a naturally-occurring tetrapeptide with anti-fibrotic effects. It modulates fibroblast proliferation and collagen synthesis, with preclinical evidence for reduced fibrosis in cardiac, renal, and dermal models. The mechanism is particularly relevant to hypertrophic scarring and keloid formation, where excessive fibroblast activity and collagen deposition drive the abnormal scar architecture. Use in clinical scarring contexts is investigational.
Matrixyl and oligopeptide-class collagen-stimulating peptides have applications in atrophic scarring (including post-acne) where the goal is to fill in the depressed scar with new collagen. Their evidence is largely cosmetic-product-driven.
BPC-157 has been discussed for general wound healing optimization, with the mechanism (angiogenesis, growth factor support, fibroblast modulation) relevant to optimizing the healing process and potentially producing better scar outcomes. Specific scar evidence is limited.
What peptides do not do for established scars: replicate the rapid effects of intralesional corticosteroid injection for hypertrophic/keloid scars; replace procedural therapy (microneedling, fractional laser) for substantial atrophic scar improvement; reverse the genetic predisposition driving keloid formation in susceptible patients; address mature deeply embedded scars without procedural disruption.
What the evidence shows
Peptide-specific evidence in scar treatment is limited. GHK-Cu has substantial general skin-remodeling evidence with established post-procedure recovery applications. AC-SDKP has strong preclinical anti-fibrotic evidence with limited human clinical translation in scarring. Matrixyl and similar peptides have cosmetic dermatology evidence for collagen stimulation. BPC-157 has wound healing evidence applicable to scar prevention more than mature scar treatment.
For evidence-validated scar therapy: intralesional corticosteroids have decades of evidence for hypertrophic and keloid scars. Silicone gel sheets have moderate evidence. Microneedling with or without radiofrequency has moderate-to-strong evidence for atrophic scars, particularly post-acne. Fractional laser resurfacing has strong evidence for atrophic scarring. PRP-microneedling combinations have growing evidence.
Peptide therapy is reasonable as an adjunct in comprehensive scar protocols, particularly post-procedure recovery, prevention of new scarring during wound healing, and as topical maintenance after procedural treatment.
What to expect
Topical peptide therapy for established scars typically requires 8-16+ weeks of consistent application before visible improvement, with combination protocols (peptide + procedural therapy + sun protection) substantially outperforming peptide monotherapy. New scars or recently healed wounds respond better than mature scars. Hypertrophic scars and keloids may stabilize or modestly improve with topical peptides plus established interventions. Atrophic scars require procedural therapy for meaningful improvement; peptides serve as adjuncts.
What to NOT expect: dramatic clearance of mature scars from peptide therapy alone, replacement of intralesional steroid injection for hypertrophic/keloid management, replacement of procedural therapy for atrophic scars, or reversal of keloid genetic predisposition.
Important caveats
Scar management benefits from dermatology consultation for moderate-to-severe scarring, particularly keloids (which may worsen with inappropriate intervention) and significant atrophic scarring (which often warrants procedural therapy). Self-directed protocols for keloid-prone patients risk worsening rather than improving the appearance.
New or actively healing wounds benefit most from optimal wound care principles (moist healing environment, sun protection, gentle cleansing) plus possibly peptide adjuncts. Mature scars (1+ years old) respond less to topical interventions than recent scars.
None of the peptides discussed is FDA-approved as a drug for scarring. Topical peptide formulations are cosmetic products or compounding-pharmacy preparations. The realistic framing: scars can be improved but rarely eliminated; comprehensive multi-modal protocols outperform single interventions.
Frequently asked questions
Can peptides remove scars?
No. Scars cannot generally be eliminated, only improved. Peptides like GHK-Cu and AC-SDKP may support better scar architecture during healing or modest improvement of established scars over months of use. Comprehensive multi-modal protocols (peptides + procedural therapy + sun protection) substantially outperform single interventions. Realistic expectation: improvement, not elimination.
What is the best peptide for scars?
GHK-Cu has the broadest applicability across scar types and is the most-discussed peptide for scar adjunct therapy. AC-SDKP has the strongest mechanistic case for hypertrophic and keloid scars due to anti-fibrotic activity, though clinical translation is limited. Matrixyl and similar collagen-stimulating peptides may help atrophic scars. Selection depends on scar type.
Will peptides help with keloid scars?
Possibly modestly, but keloids are notoriously difficult to treat and often worsen with inappropriate intervention. Intralesional corticosteroid injection has the strongest evidence for keloid management. AC-SDKP has anti-fibrotic mechanism aligned with keloid biology but limited clinical translation. Patients with keloid tendency should be managed by dermatologists familiar with keloid treatment; self-directed peptide use without specialist guidance is not appropriate for significant keloids.
Can peptides prevent scars during wound healing?
Possibly, by optimizing the healing process. BPC-157 has wound-healing optimizing effects in preclinical models. GHK-Cu supports balanced collagen synthesis during healing. The reasonable approach: standard wound care principles (clean, moist healing environment, sun protection) plus possible peptide adjuncts under clinical supervision. Peptides do not eliminate scarring risk but may modestly reduce hypertrophic scarring tendency in some patients.
Should I use peptides for acne scars or get microneedling?
Microneedling with or without radiofrequency has substantially stronger evidence for atrophic acne scars than topical peptide monotherapy. The optimal approach typically combines microneedling sessions with topical peptide adjuncts (GHK-Cu, Matrixyl) for ongoing collagen support. Peptides alone produce modest improvement for atrophic scars; procedural therapy is the foundation for meaningful improvement.
Part of these goals
Related conditions
Peptide families relevant to Scarring
Copper Peptides
A family of small copper-binding tripeptides — GHK-Cu, AHK-Cu, and palmitoyl variants — that form stable copper(II) complexes with documented effects on collagen synthesis, wound healing, and skin remodeling. Founded by Loren Pickart's 1973 isolation of GHK-Cu and now a fixture of cosmetic dermatology and the wound-care literature.
Cosmetic & Signal Peptides
The cosmetic peptide actives applied topically for skin aging, wrinkles, and pigmentation — including argireline (acetyl hexapeptide-8, the SNAP-25-targeting 'topical Botox' analog), matrixyl (palmitoyl pentapeptide-4, the matrikine collagen stimulator), syn-ake (the snake-venom-derived nicotinic-receptor antagonist), SNAP-8, vialox, rigin, and the broader cluster of palmitoylated tripeptides, palmitoylated tetrapeptides, and signal peptides used in cosmetic formulations.
Collagen Peptides
Two distinct meanings of 'collagen peptide' that consumer marketing often conflates: (1) oral hydrolyzed-collagen protein supplements (gelatin-derived powders sold for skin, hair, and joint health) with modest RCT support for skin elasticity and moisture, and (2) cosmetic 'matrikine' peptides (Matrixyl, syn-coll, palmitoyl-tripeptide-1, GHK-Cu) that stimulate fibroblast collagen synthesis topically. Different molecules, different routes, different evidence bases.
Thymic Peptides
The peptide family derived from thymic tissue and its synthetic analogs — Thymosin α-1 (Zadaxin / thymalfasin, immune modulation), Thymosin β-4 (TB-500, tissue repair through actin sequestration), Thymalin (Russian-tradition thymic-extract preparation), Thymulin (zinc-dependent thymic hormone), and Thymagen (Khavinson-program synthetic thymic peptide). Two functional branches: α-family for immune function, β-family for actin-mediated tissue repair.
Stacks that overlap
- GLOW Peptide Stack (BPC-157 + TB-500 + GHK-Cu)
GLOW is a popular pre-mixed compounded peptide blend combining BPC-157 tissue repair, TB-500 cell migration, and GHK-Cu collagen remodeling in a single 70 mg vial. Also covers the two-peptide BPC-157 + GHK-Cu pairing for practitioners sourcing vials separately.
- KLOW Peptide Stack (BPC-157 + TB-500 + GHK-Cu + KPV)
KLOW is a pre-mixed four-peptide compounded blend combining BPC-157 and TB-500 systemic repair, GHK-Cu collagen remodeling, and KPV anti-inflammatory coverage in a single 80 mg vial. It extends the popular GLOW formulation with an explicit anti-inflammatory layer.
- Wolverine Peptide Stack (BPC-157 + TB-500)
The Wolverine Stack is the most popular peptide recovery combination — BPC-157 for localized tissue repair paired with TB-500 for systemic healing, cell migration, and anti-inflammatory support.
Updated 2026-05-08